ReviewBMC complementary medicine and therapies2020
Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews.
Review in BMC complementary medicine and therapies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.European child & adolescent psychiatry · 2024Pooled it
- Medical Cannabis and Its Efficacy/Effectiveness for the Treatment of Low-Back Pain: a Systematic Review.Current pain and headache reports · 2023Pooled it
- The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes.Pharmaceutical medicine · 2022Pooled it
- Cannabis and Cannabinoid-Related Suspected Adverse Drug Reactions: Global Patterns and Cross-National Analysis Based on VigiBaseCNS drugs · 2026Article
- Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging study.Journal of psychopharmacology (Oxford, England) · 2026Article
- Ritual to relief: ethical frontiers in repurposing psychoactive substances.CNS spectrums · 2025Review
- The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia.Journal of psychopharmacology (Oxford, England) · 2025Article
- Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review.Clinical rheumatology · 2024Article
- Determination of ΔForensic toxicology · 2024Article
- Cannabinoids for Acute Pain Management: Approaches and Rationale.Current pain and headache reports · 2024Review
- A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance.Neuropsychopharmacology reports · 2024Article
- Therapeutic use of medical Cannabis in neurological diseases: a clinical update.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes.Frontiers in pharmacology · 2024Review
- Cannabis as a Source of Approved Drugs: A New Look at an Old Problem.Molecules (Basel, Switzerland) · 2023Review
- Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection.Journal of traditional and complementary medicine · 2023Review
- SPME as a green sample-preparation technique for the monitoring of phytocannabinoids and endocannabinoids in complex matrices.Journal of pharmaceutical analysis · 2023Review
- Non-pharmacological interventions for smoking cessation: analysis of systematic reviews and meta-analyses.BMC medicine · 2023Review
- Why a distinct medical stream is necessary to support patients using cannabis for medical purposes.Journal of cannabis research · 2023Article
- Review
- Effects of cannabis regulation in Switzerland: Study protocol of a randomized controlled trial.Frontiers in psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize the current available evidence surrounding therapeutic use of cannabis and cannabinoids, using evidence maps.
methodsWe searched PubMed, EMBASE, The Cochrane Library and CINAHL, to identify systematic reviews (SRs) published from their inception up to December 2017. Two authors assessed eligibility and extracted data independently. We assessed methodological quality of the included SRs using the AMSTAR tool. To illustrate the extent of use of medical cannabis, we organized the results according to identified PICO questions using bubble plots corresponding to different clinical scenarios.
resultsA total of 44 SRs published between 2001 and 2017 were included in this evidence mapping with data from 158 individual studies. We extracted 96 PICO questions in the following medical conditions: multiple sclerosis, movement disorders (e.g. Tourette Syndrome, Parkinson Disease), psychiatry conditions, Alzheimer disease, epilepsy, acute and chronic pain, cancer, neuropathic pain, symptoms related to cancer (e.g. emesis and anorexia related with chemotherapy), rheumatic disorders, HIV-related symptoms, glaucoma, and COPD. The evidence about these conditions is heterogeneous regarding the conclusions and the quality of the individual primary studies. The quality of the SRs was moderate to high according to AMSTAR scores.
conclusionsEvidence on medical uses of cannabis is broad. However, due to methodological limitations, conclusions were weak in most of the assessed comparisons. Evidence mapping methodology is useful to perform an overview of available research, since it is possible to systematically describe the extent and distribution of evidence, and to organize scattered data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.